Business
Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers
Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, June 10, 2020\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, June 10, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has signed a Memorandum Of Understanding with Cannomed Medical Cannabis Industries Ltd. (TASE: CNMD), to develop cannabis cultivars targeted to treat cancers of different types.\nThe collaboration will allow Cannabics to further expand its portfolio of cannabinoid compositions that will be extracted from Cannomed's 17 unique strains, thus contributing to its compound library matrix. Cannabics will proceed to utilize its High Throughput Screening (HTS) facility in Israel to extract the active ingredients and examine their anti-tumor properties on a variety of human cancer cells of various types.  \nCannomed, a publicly traded Israeli company, is a vertically integrated manufacturer and cultivator which holds distribution agreements in regulated markets in Europe. Cannomed cultivates 17 unique cannabis cultivars originating from proprietary genetics developed by the company. These cultivars will be assessed and screened for their anti-tumor potential. \nDr. Eyal Ballan, CTO and Co-Founder of Cannabics Pharmaceuticals said:\" Cannomed and Cannabics will collaborate to develop cannabinoid products based on Cannomed's cannabis cultivars. We have seen in the past similar collaborations yielding valuable data in pre-clinical studies held at our facility, and we are looking forward to revealing what anti-tumor potential Cannomed's strains may hold\".  \nMr. Kfir Gindi, CEO and Co-Founder of Cannomed, said: \"We are excited to be able to collaborate with Cannabics Pharmaceuticals to explore the medicina...